Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Enumeral Biomedical Holdings, Inc. ENUMQ

Healthcare Biotechnology
"Enumeral Biomedical Holdings Inc is a biopharmaceutical company engaged in the discovery and development of novel antibody immunotherapies that help the immune system fight cancer and other diseases. Its initial focus is on the development of a pipeline of next generation monoclonal antibody drugs targeting established and novel immuno-modulatory receptors."

Recent & Breaking News (OTCPK:ENUMQ)

Enumeral Reports Second Quarter Financial Results

Business Wire August 14, 2017

Enumeral Reports First Quarter Financial Results

Business Wire May 22, 2017

Enumeral and ICAV to Pursue Infectious Disease Collaboration

Business Wire April 5, 2017

Enumeral Reports Year End 2016 Financial Results

Business Wire March 28, 2017

Enumeral Completes Successful Warrant Tender Offer and Receives $3.4 Million in Gross Proceeds

Business Wire December 12, 2016

Enumeral Reports Third Quarter Financial Results

Business Wire November 10, 2016

Enumeral Appoints Wael Fayad as Chairman, President and Chief Executive Officer

Business Wire September 22, 2016

Enumeral Reports Second Quarter Financial Results

Business Wire August 12, 2016

Enumeral Announces Sale of 12% Senior Secured Promissory Notes

Business Wire August 1, 2016

Enumeral Receives Maintenance Fee to Continue License Agreement with Pieris and Enters into Definitive License Agreement

Business Wire June 6, 2016

Enumeral Reports First Quarter Financial Results

Business Wire May 13, 2016

Enumeral Announces Additional Data on Its Novel Class of PD-1 Antagonist to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting

Business Wire April 18, 2016

Enumeral and Pieris Pharmaceuticals Enter into License and Transfer Agreement

Business Wire April 18, 2016

Enumeral to Present at the 3rd Annual Jefferies Immuno-Oncology Summit

Business Wire March 31, 2016

Enumeral Reports Fourth Quarter and Year-End 2015 Financial Results

Business Wire March 30, 2016

Enumeral to Present at the Noble Financial Capital Markets' 12th Annual Investor and Equity Conference

Business Wire January 19, 2016

Enumeral and MD Anderson Enter Into Collaborative Research and Development Agreement

Business Wire January 11, 2016

Enumeral Presents Research Results for Novel Class of Anti-PD-1 Antibodies at AACR's 2016 Tumor Microenvironment Special Conference

Business Wire January 8, 2016

Enumeral to Participate in the 2016 East/West CEO Conference

Business Wire January 6, 2016

Enumeral to Present at Biotech Showcase 2016

Business Wire January 5, 2016